(Q44079578)

29 November 2017

ACC/AHA/NHLBI clinical advisory on the use and safety of statins (English)

1 reference

American Heart Association

29 November 2017

series ordinal

8

object named as

American Heart Association

1 reference

American College of Cardiology

29 November 2017

series ordinal

7

object named as

American College of Cardiology

1 reference

29 November 2017

2

Sidney C Smith

1 reference

29 November 2017

1

Richard C Pasternak

1 reference

29 November 2017

5

James I Cleeman

1 reference

29 November 2017

6

Claude Lenfant

1 reference

29 November 2017

4

Scott M Grundy

1 reference

29 November 2017

C Noel Bairey-Merz

3

1 reference

29 November 2017

National Heart, Lung and Blood Institute

series ordinal

9

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Journal of the American College of Cardiology

29 November 2017

1 reference

29 November 2017

40

1 reference

29 November 2017

567-572

1 reference

29 November 2017

3

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Statins and risk of polyneuropathy: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Learning from the cerivastatin experience

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation: Lipid-Lowering and Immunosuppressive Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Does differing metabolism by cytochrome p450 have clinical importance?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Safety of combined pravastatin-gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

Lovastatin increases exercise-induced skeletal muscle injury

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902030-2

7 January 2021

10.1016/S0735-1097(02)02030-2

Identifiers

DOI

1 reference

29 November 2017

1 reference